Patricia Natalia Moretti

Patricia Natalia Moretti

Auto-generated profile, based on publicly available information

Patricia Natalia Moretti

Department of Morphology and Genetics, Universidade Federal de São Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
BCBruno Messina Coimbra
Bruno Messina Coimbra
CCCarolina Muniz Carvalho
Carolina Muniz Carvalho
PMPatricia Natalia Moretti
Patricia Natalia Moretti
MMMarcelo Feijó Mello
Marcelo Feijó Mello
SBSintia I. Belangero
Sintia I. Belangero

31 August 2018 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
MSMarcos Leite Santoro
Marcos Leite Santoro
VOVanessa Ota
Vanessa Ota
SJSimone de Jong
Simone de Jong
CNCristiano Noto
Cristiano Noto
LSLeticia M. Spindola
Leticia M. Spindola
GBGerome Breen
Gerome Breen
In this study, we aimed to test if the schizophrenia (SCZ) polygenic risk score (PRS) was associated with clinical symptoms in (a) the first episode of psychosis pre-treatment (FEP), (b) at nine weeks after initiation of risperidone treatment (FEP-9W) and (c) with the response to risperidone. We performed a detailed clinical assessment of 60 FEP patients who were antipsychotic-naive and, again, after nine weeks of standardized treatment with risperidone. After blood collection and DNA isolation, the samples were genotyped using the Illumina PsychArrayChip and then imputed. To calculate PRS, we used the latest available GWAS summary statistics from the Psychiatric Genomics Consortium wave-2 SCZ group as a training set. We used Poisson regression to test association between PRS and clinical measurements correcting for the four principal components (genotyping). We considered a p-value < 0.0014 (Bonferroni correction) as significant. First, we verified that the schizophrenia PRS was also able to distinguish cases from controls in this south-eastern Brazilian sample, with a similar variance explained to that seen in Northern European populations. In addition, within-cases analyses, we found that PRS is significantly correlated with baseline (pre-treatment) symptoms, as measured by lower clinical global assessment of functioning (−GAF), higher depressive symptoms and higher scores on a derived excitement factor. After standardized treatment for nine weeks, the correlation with GAF and the excitement factor disappeared while depressive symptoms became negatively associated with PRS. We conclude that drug (and other treatments) may confound attempts to understand the aetiological influence on symptomatology of polygenic risk scores. These results highlight the importance of studying schizophrenia, and other disorders, pre-treatment to understand the relationship between polygenic risk and phenotypic features.

22 October 2015 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
CNCristiano Noto
Cristiano Noto
VOVanessa Kiyomi Ota
Vanessa Kiyomi Ota
MSMarcos Leite Santoro
Marcos Leite Santoro
EGEduardo Sauerbronn Gouvea
Eduardo Sauerbronn Gouvea
PSPatricia Natalia Silva
Patricia Natalia Silva
MMMichael Maes
Michael Maes

29 October 2013 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PSPatricia Natalia Silva
Patricia Natalia Silva
TFTatiane Katsue Furuya
Tatiane Katsue Furuya
IBIanna Lacerda Braga
Ianna Lacerda Braga
LRLucas Trevizani Rasmussen
Lucas Trevizani Rasmussen
RLRoger Willian Labio
Roger Willian Labio
MSMarilia de Arruda Cardoso Smith
Marilia de Arruda Cardoso Smith
Alzheimer's disease (AD) is the most common form of dementia in elderly. Chaperones may have a crucial role in AD due to their involvement in protein quality control, folding, and degradation. In this study, we investigated the mRNA and promoter DNA methylation levels of two chaperones, HSPA8 and HSPA9, in postmortem brain tissue (entorhinal and auditory cortices and hippocampus) from healthy elderly and AD subjects as well as in peripheral blood of healthy elderly and AD patients. mRNA quantification was performed by qRT-PCR and DNA methylation by mass spectrometry. In the peripheral blood, we did not observe a significant difference in HSPA8 and HSPA9 expression between elderly controls and AD. A significant downregulation of HSPA8 and HSPA9 was observed in AD across the three brain regions compared to the controls, suggesting their participation in AD pathogenesis. However, no important DNA methylation differences were observed, suggesting that other mechanism may be involved in controlling these genes expression.

1 December 2012 in Neurochemistry International
Verified
Journal Article
Closed access
TFTatiane Katsue Furuya
Tatiane Katsue Furuya
PSPatrícia Natália Oliveira da Silva
Patrícia Natália Oliveira da Silva
SPSpencer Luiz Marques Payão
Spencer Luiz Marques Payão
LRLucas Trevizani Rasmussen
Lucas Trevizani Rasmussen
RLRoger Willian de Labio
Roger Willian de Labio
MSMarilia de Arruda Cardoso Smith
Marilia de Arruda Cardoso Smith

6 January 2011 in Cancer Investigation
Verified
Journal Article
Closed access
CGCarolina Oliveira Gigek
Carolina Oliveira Gigek
LLLuara Carolina Frias Lisboa
Luara Carolina Frias Lisboa
MLMariana Ferreira Leal
Mariana Ferreira Leal
PSPatricia Natalia Oliveira Silva
Patricia Natalia Oliveira Silva
ELEleonidas Moura Lima
Eleonidas Moura Lima
MSMarilia de Arruda Cardoso Smith
Marilia de Arruda Cardoso Smith
Here, we first evaluated SMARCA5 expression and promoter DNA methylation in gastric carcinogenesis. lmmunohistochemistry and methylation-specific PCR were analyzed in 19 and 48 normal mucosa and in 52 and 92 gastric cancer samples, respectively. We observed higher immunoreactivity of SMARCA5 in gastric cancer samples than in normal mucosa. Moreover, SMARCA5 promoter methylation was associated with the absence of protein expression. Our findings suggest that SMARCA5 has a potential role in proliferation and malignancy in gastric carcinogenesis.